In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-Octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT

European Journal of Nuclear Medicine

Volumn 23, Issue 10, 1996, Pages 1388-1399

  Virgolini, Irene ^a   Angelberger, Peter ^b   Li, Shuren ^a   Yang, Qiong ^a   Kurtaran, Amir ^a   Raderer, Markus ^a   Neuhold, Nikolaus ^a   Kaserer, Klaus ^a   Leimer, Maria ^a   Peck Radosavljevic, Markus ^a   Scheithauer, Werner ^b   Niederle, Bruno ^a   Eichler, Hans Georg ^a   Valent, Peter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b ARC SEIBERSDORF RESEARCH GMBH   (Austria)

Author keywords

DTPA D Phe 1 octreotide; Imaging studies; In vitro binding; Octreotide; Tyr 3 octreotide

Indexed keywords

IODINE 123; SOMATOSTATIN DERIVATIVE;

ARTICLE; BINDING AFFINITY; CARCINOID; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE TUMOR; ISOTOPE LABELING; SCINTIGRAPHY; TUMOR; TUMOR CELL LINE;

ADOLESCENT; ADULT; AGED; CARCINOID TUMOR; FEMALE; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASMS; OCTREOTIDE; PENTETIC ACID; RECEPTORS, SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 10244247811     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01367597     Document Type: Article

References (27)

1. Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1556-1563.
2. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 119: 77-79.
3. Plewe G, Beyer J, Krause U, et al. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet 1984; ii: 782-784.
4. Liebow C, Reilly C. Serrano M, Schally AV. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Procc Natl Acad Sci USA 1989; 86: 2003-2007.
5. Virgolini I, Yang Q, Li SR, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumour cell membrane receptors. Cancer Res 1994; 54: 690-700.
6. Yamada Y, Post SR, Wang K, et al. Cloning and functional characterization of family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA 1992; 89: 251-255.
7. Yamada Y, Reisine T, Law SF, et al. Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 1992; 6: 2136-2142.
8. Corness JD, Demchyshyn LL, Seeman P, et al. A human somatostatin receptor (SSTR3). located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS Lett 1993; 321: 279-284.
9. Demchyschyn LL, Srikant CB, Sunahara RK, et al. Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20. Mol Pharmacol 1993; 43: 894-901.
10. Rohrer L, Raulf F, Bruns C, et al. Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci USA 1993; 90: 4196-4200.
11. Yamada Y, Kagimoto S, Yasuda K, et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 1993; 195: 844-852.
12. Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome. N Engl J Med 1986; 315: 663-666.
13. Maton PN, moderator. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumours of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110: 353-364.
14. Krenning EP, Bakker WH, Breeman WAP, et al. Localization of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; I: 242-244.
15. Lamberts SWJ, Bakker WH, Reubi JC, et al. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323: 1246-1249.
16. 111In-DTPA-D-Phe-1-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumours: synthesis, radiolabeling and in vitro validation. Life Sci 1991; 49: 1583-1591.
17. Krenning EP, Bakker WH, Kooij PPM, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33: 652-658.
18. 123I-Tyr-3-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
19. Eijck CHJ, Krenning EP, Bootsma A, et al. Somatostatin receptor scintigraphy in primary breast cancer. Lancet 1994; 343: 640-643.
20. 123I-labelled LDL. J Nucl Med 1991; 32: 2132-2138.
21. 123I-labeled vasoactive intestinal peptide (VIP) for the localization of intestinal adenocarcinomas and encocrine tumors. N Engl J Med 1994; 331: 1116-1121.
22. 111In-labeled HDL to platelets from normolipemic volunteers and patients with heterozygous familial hypercholesterolemia. Arteriosclerosis 1982; 12: 849-861.
23. 2 receptor. J Biol Chem 1992; 267: 12700-12708.
24. Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949; 51: 660-672.
25. Smith-Jones PM, Stolz B, Bruns C, et al. Gallium-67/gallium-68-DFO-octreotide: a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumours: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994; 35: 317-325.
26. Krohn KA, Welch MJ. Studies of radioiodinated fibrinogen II. Lactoperoxidase iodination of fibrinogen and model compounds. J Appl Radiat Isotop 1974; 25: 315-325.
27. Bosee R, Escher E. Synthesis of radioiodinated ligands with high affinity and selectivity for mu- and delta-opioid receptors. In: Peptides 1990. Proc. 21st Eur Pept Symp. Leiden: Escom Sci; 1991; 632-634.